Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKCEA-ANGPTL3-LRx in Familial Chylomicronemia Syndrome
NCT03360747Phase 2Completed
- Sponsor
- Akcea Therapeutics
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of vupanorsen in familial chylomicronemia syndrome (FCS), sponsored by Akcea Therapeutics. Started Dec 2017; status: completed.
02
Drugs
vupanorsen
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT03360747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360747.